Zoetis Inc. (ZTS) Net Income CAGR:4.97%(TTM)
The net income cagr for Zoetis Inc. (ZTS) is +4.97% over the latest trailing 12-month period. Net income CAGR uses precomputed financial statement history.
The net income cagr for Zoetis Inc. (ZTS) stock is 4.97% over the past 12 months. The 3 year average growth rate is 8.47% and the 5 year cagr is 8.30%. Net income CAGR shows how Zoetis Inc.'s bottom-line profitability has grown. This reflects the company's ability to convert revenue into profits after all expenses.
ZTS Net Income CAGR Chart
Zoetis Inc. (ZTS)
ZTS Net Income CAGR History
| Year | Start Net Income | End Net Income | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $2.49B | $2.67B | +$187.00M | +7.52% | +7.52% |
| 2024 | $2.34B | $2.49B | +$142.00M | +6.06% | +6.06% |
| 2023 | $2.11B | $2.34B | +$230.00M | +10.88% | +10.88% |
| 2022 | $2.04B | $2.11B | +$77.00M | +3.78% | +3.78% |
| 2021 | $1.64B | $2.04B | +$399.00M | +24.36% | +24.36% |
| 2020 | $1.50B | $1.64B | +$138.00M | +9.20% | +9.20% |
| 2019 | $1.43B | $1.50B | +$72.00M | +5.04% | +5.04% |
| 2018 | $864.00M | $1.43B | +$564.00M | +65.28% | +65.28% |
| 2017 | $821.00M | $864.00M | +$43.00M | +5.24% | +5.24% |
| 2016 | $339.00M | $821.00M | +$482.00M | +142.18% | +142.18% |
| 2015 | $583.00M | $339.00M | $-244.00M | -41.85% | -41.85% |
| 2014 | $504.00M | $583.00M | +$79.00M | +15.67% | +15.67% |
| 2013 | $436.00M | $504.00M | +$68.00M | +15.60% | +15.60% |
| 2012 | $245.00M | $436.00M | +$191.00M | +77.96% | +77.96% |
| 2011 | $110.00M | $245.00M | +$135.00M | +122.73% | +122.73% |
| 2010 | $-100.00M | $110.00M | +$210.00M | +0.00% | N/A |
Quarterly Net Income — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $601.00M | -0.3% | -4.8% |
| Q4 2025 | $603.00M | -16.4% | +3.8% |
| Q3 2025 | $721.00M | +0.4% | +5.7% |
| Q2 2025 | $718.00M | +13.8% | +15.1% |
| Q1 2025 | $631.00M | +8.6% | +5.3% |
| Q4 2024 | $581.00M | -14.8% | +10.7% |
| Q3 2024 | $682.00M | +9.3% | +14.4% |
| Q2 2024 | $624.00M | +4.2% | -7.0% |
| Q1 2024 | $599.00M | +14.1% | +8.5% |
| Q4 2023 | $525.00M | -11.9% | +13.9% |
| Q3 2023 | $596.00M | -11.2% | +12.7% |
| Q2 2023 | $671.00M | +21.6% | +26.8% |
| Q1 2023 | $552.00M | +19.7% | -7.2% |
| Q4 2022 | $461.00M | -12.9% | +11.4% |
| Q3 2022 | $529.00M | +0.0% | -4.2% |
| Q2 2022 | $529.00M | -11.1% | +3.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck